Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report

In patients with metastatic melanoma the advent of targeted therapy and immune checkpoint inhibitors has transformed the management of advanced and metastatic disease, resulting in improved outcomes. Neopterin is a biomarker of immune activation increased in cancer as well as in other conditions ass...

Full description

Saved in:
Bibliographic Details
Published in:Pteridines 2020-01, Vol.31 (1), p.151-157
Main Authors: Bartoušková, Marie, Hrouzková, Michaela, Čtvrtlík, Filip, Petrová, Pavla, Rušarová, Nikol, Kučerová, Kateřina, Vernerová, Andrea, Melichar, Bohuslav, Študentová, Hana
Format: Article
Language:English
Subjects:
Activation
Biomarkers
BRAF inhibitors
Case reports
MEK inhibitors
Melanoma
Metastasis
metastatic melanoma
neopterin
Skin cancer
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In patients with metastatic melanoma the advent of targeted therapy and immune checkpoint inhibitors has transformed the management of advanced and metastatic disease, resulting in improved outcomes. Neopterin is a biomarker of immune activation increased in cancer as well as in other conditions associated with immune activation. We present a case of a patient with advanced metastatic melanoma responding to the combination targeted therapy with dabrafenib and trametinib. The treatment was complicated by a fever that was accompanied by a marked rise in serum and urinary neopterin concentrations. Present case report illustrates not only the efficacy of combined targeted therapy, but also the utilization of neopterin measurements in the diagnosis and monitoring of pyrexia in patients with metastatic malignant melanoma.
ISSN:0933-4807
2195-4720
DOI:10.1515/pteridines-2020-0009